Two Indian pharmaceutical companies, Cipla and Glenmark, are pulling back certain products from the American market due to manufacturing concerns, according
to the US Food and Drug Administration (USFDA).
A New Jersey-based subsidiary of Cipla is recalling 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution due to "short fill", news agency
PTI reported, quoting the latest Enforcement Report issued by the US health regulator.
Produced at the company's Indore SEZ plant, this medication is used to manage symptoms associated with lung diseases, such as asthma, chronic bronchitis and
emphysema.
Cipla USA decided to recall the affected lot following complaints of less fill volume in respule and few drops of liquid observed in the intact pouch, the USFDA
said, adding that the drug maker initiated the Class II recall in the US market on March 26 this year.
A recent UNISON survey has unearthed disturbing findings regarding the prevalence of sexual harassment among NHS staff across the UK. With data collected from
over 12,000 healthcare workers, the survey sheds light on the challenges faced by frontline workers in their workplace environments.
Approximately 10 per cent of healthcare professionals reported instances of sexual harassment during their tenure, with nearly 29 per cent of those experiencing
harassment also reporting incidents of sexual assault.
Shockingly, 50 per cent of respondents reported being leered at or subjected to suggestive gestures, while a quarter faced unwelcome sexual advances or demands
for favors.
The most common complaint, voiced by 61 per cent of those affected, was the experience of unwanted crude banter or jokes in the workplace.
